BIVI logo

BioVie, Inc. Common Stock


BIVI: BioVie Inc is a clinical-stage company developing innovative drug therapies to treat chronic debilitating conditions including liver disease and neurological and neuro-degenerative disorders and certain cancers. The Company is conducting a potentially pivotal Phase 3 randomized, double-blind, placebo-controlled, parallel-group, multicenter study to evaluate NE3107 in patients who have mild to moderate Alzheimer's disease. BIV201 has the potential to improve the health of thousands of patients suffering from life-threatening complications of liver cirrhosis due to hepatitis, non-alcoholic steatohepatitis and alcoholism.


Show BIVI Financials

Consumer Interest
SEC Filings

Recent trades of BIVI by members of U.S. Congress

Quiver Logo

No Congress Trading data for this ticker

Congress Trading Dashboard

Recently reported changes by institutional investors

Quarterly net insider trading by BIVI's directors and management

Government lobbying spending instances

Quiver Logo

No Corporate Lobbying instances for this ticker

Corporate Lobbying Dashboard
U.S. Patents

New patents grants

  • Patent Title: Treatment of ascites Jun. 21, 2022
  • Patent Title: Treatment of ascites May. 23, 2017
Government Contracts

Federal grants, loans, and purchases

Quiver Logo

No Government Contracts for this ticker

Government Contracts Dashboard

Number of mentions of BIVI in WallStreetBets Daily Discussion


Recent insights relating to BIVI

CNBC Recommendations

Recent picks made for BIVI stock on CNBC

Top ETF Holders

ETFs with the largest estimated holdings in BIVI

Corporate Flights

Flights by private jets registered to BIVI